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Pre-eclampsia is a pregnancy complication characterized by hypertension and proteinuria. There are several factors associated
with an increased risk of developing pre-eclampsia, one of which is increased uterine artery resistance, referred to as “notching”.
However, some women do not progress into pre-eclampsia whereas others may have a higher risk of doing so. The placenta,
central in pre-eclampsia pathology, may express genes associated with either protection or progression into pre-eclampsia. In
order to search for genes associated with protection or progression, whole-genome proﬁling was performed. Placental tissue from
15 controls, 10 pre-eclamptic, 5 pre-eclampsia with notching, and 5 with notching only were analyzed using microarray and
antibody microarrays to study some of the same gene product and functionally related ones. The microarray showed 148 genes to
be signiﬁcantlyaltered between thefourgroups. In thepreeclamptic group comparedto notch only,there wasincreased expression
of genes related to chemotaxis and the NF-kappa B pathway and decreased expression of genes related to antigen processing
and presentation, such as human leukocyte antigen B. Our results indicate that progression of pre-eclampsia from notching may
involve the development of inﬂammation. Increased expression of antigen-presenting genes, as seen in the notch-only placenta,
may prevent this inﬂammatoryresponse and, thereby, protect the patient from developing pre-eclampsia.
1.Introduction
In the western world, 3–7% of all pregnancies are aﬀected
by pre-eclampsia (PE). The etiology of PE is still poorly
understood, and several theories have been put forward
[1–4].
PE is considered a two-stage disease [5, 6]. The ﬁrst stage
is characterized by poor placentation resulting from shallow
invasion of the trophoblasts into the maternal spiral arteries.
Instead of the low-resistance high-ﬂow system seen in the
normal placenta, the PE placenta has increased resistance,
and a decreased blood ﬂow and uneven perfusion leads to
hypoxia, ischemia, and reperfusion injuries in the placenta
[5, 6].
The second stage of PE is characterized by a general
vascular endothelial damage, which eventually aﬀects all
maternal organs. Transition from stage one, to stage two
of the disease is typically seen before 35 gestational weeks
(GW) in early onset PE. Placentas from early onset PE
moreoftenshowhistologicalpathologicalﬁndingsassociated
with poor placental perfusion, such as infarcts and chronic
inﬂammation [7]. In contrast, placentas from late-onset
PE, manifest after 35GW, rarely show these pathological
ﬁndings. The placental factors linking the ﬁrst and second
stage are not fully known. However, some placental factors
that may participate in the progression to the second stage
have been identiﬁed [8].
Increased vascular resistance in the uterine arteries is
associated with decreased placental perfusion. The former
can be measured by Doppler ultrasound as early as 12GW
andquantiﬁedusingpulsatilityindex(PI)whichiscalculated
by subtracting the peak systolic velocity from the end2 Journal of Pregnancy
Table 1: Clinical characteristics of patients at delivery.
Control PE PE/N Notch
N 15 10 5 5
Age (y) 31 (24–37) 29 (22–34) 32 (27–39) 32 (23–39)
Gestational age (days) 280 (253–295) 264 (227–285) 241 (204–283) 250 (219–284)
Systolic pressure (mmHg) 120 (110–135) 159 (140–170) 151 (145–160) 110 (115–120)
Diastolic pressure (mmHg) 75 (60–80) 105 (100–120) 100 (98–105) 78 (60–80)
Proteinuria (g/l) 0 (0–0.3) 3 (0.3–5) 3 (0.3–5) 0 (0-1)
Birth weight (g)a 3780 (2900–4315) 3100 (2500–3860) 1590 (1100–3430) 2790 (1400–3850)
GenderM:F 7:8 5:5 2:3 3:2
Pulsatility index NA 0.69 (0.59–0.73) 0.99 (0.67–1.43) 0.93 (0.83–1.76)
Mode of delivery (VD:CS) 15:0 7:3 3:2 4:1
All data is presented as median (range) except child gender (Male:Female) and mode of delivery (VD:CS). A Kruskal-Wallis post hoc Dunn test was used to
calculate statistical diﬀerences between the groups. PE: pre-eclampsia, PE/N: pre-eclampsia with bilateral notching, NA: not available, VD: vaginal delivery,
and CS: caesarian section. aAs i g n i ﬁ c a n td i ﬀerence between controls versus PE/N (P<. 05).
diastolic velocity and dividing the diﬀerence by the maxi-
mum velocity averaged over one cardiac cycle. Increasing PI
suggests increased vascular resistance, which has been shown
tocorrelate well with early onset and severe PE[9]. Increased
uterine artery resistance is also correlated with a diastolic
pattern described as “notching” detected in early pregnancy
[10]. As many as 15–20% of all pregnancies show signs of
bilateral notch at 18GW, although this number decreases to
about 5% when patients are re-evaluated at 24GW [11]. The
presence of bilateral notch has been shown to be a predictor
of early onset PE [12]. Although persisting notching is
a predictor of women with increased risk of developing PE
later in their pregnancies, not all of them do [9, 13, 14].
Thus it seems possible that women with notching, who do
not develop PE later in their pregnancies, may be protected
from doing so by mechanisms that could include expression
of beneﬁcial genes or inhibition of the expression of harmful
ones in their placentas.
In a previous study of a small group of candidate
genes, we provided evidence that notching may be an early
stage of PE [15]. In the present study, we have used a
comprehensive whole-genome oligonucleotide array system
to proﬁle the placental gene expression in two types of notch
patients and PE pregnancy placentas to search for placental
g e n e so rg r o u p so fg e n e st h a tm i g h ta l t e rt h ep r o g r e s s i o n
to PE.
2.MaterialandMethods
2.1. Sample Collection. Placental samples were obtained
from 35 women admitted to Lund University Hospital (15
controls, 10 PE without notch, 5 PE with notches, and
5 notches without PE, Table 1). This, sample set that we
studied earlier [16]. Sampling was performed after written
consent and the approval by the Swedish Ethical Committee
Review Board were given. Pre-eclampsia was deﬁned as
blood pressure above 140/90mmHg and proteinuria above
0.3g/l [17]. Uterine artery Doppler velocimetry was per-
formed at 18 and 24GW, using a Philips HDI 5000 system
(Philips Medical Systems, Vothell, USA). The uterine artery
was visualized with color Doppler imaging on each side
at the level of crossing with the external iliac artery. The
pulsatility index (PI) was computed automatically by the
system in both the right and left uterine arteries. The
presence or absence of a diastolic notch in the waveform
was assessed visually. Only patients with bilateral notching
were included in the notch group. A 10 × 10 × 10mm
cube of villous tissue from one cotyledon was removed
after delivery and immediately put on dry ice. Since the
placenta is a very heterogeneous tissue and the placenta gene
expression diﬀers between diﬀerent parts of the placenta,
sampling was always performed in a central portion of
the placenta in an attempt to keep the tissue samples as
homogenous as possible [18]. Maternal blood samples, 6ml,
were collected before delivery into PAXgene blood RNA
tubes (Qiagen, Solna, Sweden) according to the manufac-
turer’s instructions. Samples were stored at −80◦Cu n t i l
usage.
2.2. RNA Extraction
2.2.1. Tissue. RNA was extracted with TRIzol according to
themanufacturer’s instructions (Invitrogen,Carlsbad, USA).
Brieﬂy, 120–150mg of placental tissue was homogenized
i n2 - 3 m lT R I z o lo ni c e .C e l l u l a rd e b r i sw a sr e m o v e db y
spinning the samples at 12000g for 10 minutes after which
chloroform was added. The aqueous phase containing the
RNA was isolated. To precipitate the RNA, 2-propanol
with sodium citrate was used. The sodium citrate was
added in order to remove contaminating proteoglycans
and polysaccharides. The RNA pellet was washed once
with 75% (v/v) ethanol, and then allowed to air dry. The
pellet was dissolved in RNase-free water and assayed using
a NanoDrop spectrophotometer (Thermo Fisher Scientiﬁc,
Waltham, USA). To remove residual phenol, the RNA was
again precipitated with 2-propanol, and washed three times
with 75% (v/v) ethanol before it was used.
RNA integrity was assessed on a 1% (w/v) agarose gel
containing 6.7% (v/v) formaldehyde run with 1 × MOPS
buﬀer. RNA samples were required to have clear bands atJournal of Pregnancy 3
28Sand 18S,respectively, with no otherbands present onthe
gel. No samples with poor RNAquality were used for further
analysis.
2.2.2. Blood. RNA was extracted using PAXgene Blood RNA
Kit according to the manufacturer’s instructions (Qiagen).
Brieﬂy, samples were centrifuged and the supernatant dis-
cardedafter which the pellet was resuspended in 5ml RNase-
free water. Following centrifugation, proteins were removed
by the addition of proteinase K. Samples were added to
PAXgene columns and washed with the corresponding
buﬀers after which RNA was eluted in 80μl elution buﬀer.
RNA was quantiﬁed and assessed as above.
2.3. DNA Microarrays. Microarrays were produced at the
Swegene DNA Microarray Resource Center, Department
of Oncology, Lund University, Sweden (http://swegene.
onk.lu.se). Human array-ready oligonucleotidelibraries Ver-
sion 2.1 and Version 2.1.1-upgrade, comprising approxi-
mately 27, 000 unique probes, were obtained from Operon
(Operon Biotechnologies, Germany). Probes were dis-
solved in Corning Universal Spotting solution (Corning,
Acton, MA) and printed on aminosilane coated glass
slides (Corning) using a MicroGrid2 robot (BioRobotics,
Cambridgeshire, UK) equipped with MicroSpot 10K pins
(BioRobotics, Cambridgeshire, UK). Following printing,
arrayswere leftinadesiccatortodryfor48hours, rehydrated
for 1 second over steaming water, snap-dried on a hot plate
(98◦C), and UV cross-linked (800mJ/cm2).
Complementary DNA for microarray was synthesized
and labeled with ﬂuorescence, Cy3 or Cy5 (Amersham Bio-
sciences, Buckinghamshire, UK), using the Promega Chip-
Shot labeling system according to the manufacturers’
instructions (Corning). Brieﬂy, Cy3- and Cy5-labeled cDNA
was prepared using 5μg total RNA. Pretreatment of
arrays, hybridization, and posthybridization wash carried
out according to the manufacturers’ instructions (Promega
ChipShot labeling system andP r o m e g a ,M a d i s o n ,U S A ) .
All experimental samples were hybridized individually
against a common reference (a placental sample from a nor-
motensive pregnancy without any complications). Samples
w e r er u ni ns i n g l ee x p e r i m e n t s .
Samples were run individually (i.e., no groups were
pooled). The arrays were not run in replicates, each sample
was only assessed once.
2.3.1. Imaging and Data Analysis. To image hybridized
microarray slides, an Agilent G2565AA microarray scanner
(AgilentTechnologies,PaloAlto,USA)wasused.Imageanal-
ysis was done in GenePix Pro 4.0 (Axon Instruments Inc.,
Foster City, USA). Fluorescence intensities were extracted
and spots with grains of dust and other contaminants were
identiﬁed and eliminated. The retrieved intensity values
were uploadedinto BioArray Software Environment (BASE)
(http://base.thep.lu.se) for further analysis [19]. In BASE,
Cy3 and Cy5 signals were corrected for background using
the median spot pixel intensity and median local back-
ground pixel intensity. Fluorescence ratios were calculated
as Cy3/Cy5 and log (base 2) transformed. Spots were
ﬁltered for intensity below 350 in any of the two channels
and biased spots identiﬁed in Genepix. Following that,
ﬁltering spots were normalized using Lowess normalization
and then corrected for common reference bias using gene
median centering, after which the data was ﬁltered for fold
c h a n g ee q u a lt oo ra b o v e1 . 5 .[ 20]. Group comparison was
conducted using a false discovery rate modiﬁed t-test [21].
A P-value <.005 was considered statistically signiﬁcant. The
data has been uploaded by MIAMExpress submission and
annotation tool European Molecular Biology Laboratory
European Bioinformatic Institute Microarray Informatics
￿
2.3.2. Bioinformatic Analysis. We used Gene Ontology (GO,
http://www.geneontology.org/), the Kyoto Encyclopedia of
Genes and Genomes (KEGG, http://www.genome.jp/kegg/),
and InterPro (http://www.ebi.ac.uk/interPro/) to classify sig-
niﬁcantly altered genes according to their molecular func-
tion, their participation in signaling pathways, and the
presence of protein domains, respectively, as previously
described [15]. The genes were also annotated and analyzed
using the database for annotation, visualization, and inte-
grated discovery (DAVID) with the whole human genome,
approximately 27,000 genes, as background [22]. Statistical
diﬀerences in GO or KEGG were determined by comparing
the expected number of genes in each GO-category/KEGG-
pathway (as determined by the background genome) with
the actual number of altered genes as determined by the
microarray results. In each category, both activating and
suppressing genes may be present. Altered categories as well
as the genescorresponding to themare listed in Table 3.AP-
valuebelow .05withafoldchangeabove2wasusedascutoﬀ.
2.4. Quantitative Real-Time PCR
2.4.1. cDNA Synthesis. cDNA was synthesized from total
RNA using reverse transcriptase according to the manufac-
turer’s instructions (Applied Biosystems, Foster City, USA)
as previously described [16]. cDNA samples were stored in
−20◦Cu n t i lu s a g e .
2.4.2. Real-Time Assays. Taqman Gene Expression
Assays were ordered from Assays-on-Demand (TGFB1:
Hs00171257 m1, HP: Hs00978377 m1, TIP30: Hs00185131
m1 and INHA: Hs00171410 m1; Applied Biosystems, Foster
City, USA).Primers were designed to target exon boundaries
in order to avoid amplifying genomic DNA. Transcripts
were assayed using an ABI Prism 7000 sequence detection
system and quantiﬁed by using a standard curve by means
of a 4-fold dilution series (80–0.08ng). Each sample was
run individually, and the reactions were run in duplicates
as previously described [16]. Samples were removed from
statistical analysis if only one of the two reactions gave
a reliable result or if the standard deviation (SD) between
the duplicates was above 2SD.
2.4.3. Analysis. β-actin was used to normalize the real-time
PCR data. A Kruskal-Wallis test was used to determine the
statistical distribution between the four groups (PE, PE with
notching, PE without notching, notching without PE, and4 Journal of Pregnancy
Table 2: The most signiﬁcantly altered genes in the microarray experiments, with their respective gene ontology classiﬁcation (where
available).
Gene symbol Genebank P-value Gene ontology FC
PE compared to control
∗C1orf90 NM 032648 7.0 × 10
−5 1.9
∗TGFB1 NM 000660 .0011
Cell death, inﬂammatory
response, negative
regulation of cell
proliferation, and so forth
3.5
∗INHA NM 002191 .0014
Cytokine activity, hormone
activity, hemoglobin
biosynthetic process,
cell-cell signaling,and so
forth
2.3
FBN2 NM 001999 .0015
Extracellular matrix
structural constituent,
proteinaceous extracellular
matrix
−2.2
HOXA13 NM 000522 .0027 Skeletal development
hematopoiesis
2.1
FLT1 NM 002019 .03
Vascular endothelial
growth factor receptor
activity and positive
regulation of cell
proliferation
2.4
PE compared to notch
∗NCAM1 NM 000615 3.9 × 10−4
Cell adhesion, plasma
membrane, synaptic
transmission
1.7
∗TIP30 NM 006410 .00048
Regulation of angiogenesis,
regulation of apoptosis,
RNA polymerase II
transcription factor
activity, and so forth
2.2
CCL8 NM 005623 .00060
Chemokine activity,
calcium ion transport,
chemotaxis, signal
transduction, and so forth
3.4
LY6D NM 003695 .00091 Cell adhesion 3.3
ATP2A2 NM 001681 .0013
Calcium transporting
ATPase activity, cell
adhesion, integral to
plasma membranes, and so
forth
−2.4
SMARCA5 NM 003601 .0015
RNA polymerase II
transcription factor
activity, DNA binding,
transcription initiation,
and so forth.
2.4
PE with notch compared to notch
KLHL31 NM 001003760 .0019 1.9
SPP1 NM 000582 .0020 Cell adhesion, and so forth −2.8
TBCD NM 005993 .0047 Chaperon binding −1.9
CIDEA NM 001279 .0055 Cell death, apoptotic,
program, and so forth
−1.8
Notch compared to controls
TUBG1 NM 001070 .0020
Structural constituent of
cytoskeleton, protein
binding, and so forth
−3.4Journal of Pregnancy 5
Table 2: Continued.
Gene symbol Genebank P-value Gene ontology FC
GAL3ST4 NM 024637 .0022
Cell-cell signaling,
proteoglycan biosynthetic
process, and so forth
−2.7
CD320 NM 016579 .0027 Regulation of cell growth −3.7
∗HP NM 005143 .0061
Cellular iron ion
homeostasis and defense
response
−3.8
FC: fold change. All FC values are relative to the ﬁrst group in the comparison. PE: pre-eclampsia
∗Gene validated with quantitative real-time PCR.
Table 3: GO categories. All genes on the array were assigned to their respective GO categories and used as a background for the analysis.
GO Term GO ID P-value FC
PE compared to controls
Transcription factor binding GO:0008134 .0019 3.6
JUNB, CALCOCO1, ATF5, HOXC6, PARD6A, NR2F2, FAF1
Negative regulation of signal transduction GO:0009968 .0027 8.5
FRZB, ZA20D1, and RHOH
Transcription corepressor activity GO:0003714 .0086 6.2
JUNB, ATF5, HOXC6, and NR2F2
Steroid hormonereceptor activity GO:0003707 .014 7.8
PGRMC2, NR2F2, NR1D2
PE compared to notch
Transcriptional activator activity GO:0016563 .0005 3.2
CALCOCO1, SMARCC1, PIAS1, SRCAP, RUNX1, MAML3, and DYRK1B
Muscle ﬁber development GO:0048747 .0058 10.6
IGFBP3, and CACNA1H
Cell motility GO:0006928 .012 2.4
FLNA, FEZ2, CRK, MAPK14, PXN, and TLN1
Positive regulation of transcription, DNA-dependent GO:0045893 .012 3.6
PIAS1, SMARCC1, RUNX1, MAML3 and DYRK1B
Glucosamine metabolism, GO:0006041 .018 7.1
CTBS and NAGK
PE with notch compared to notch
Chemotaxis / Locomotory behavior GO:0006935 .021 6.7
CCBP2, SPP1, and CMKLR1
Positive regulation of cell proliferation GO:0008284 .026 6.1
SPP1 and EBI3
Vesicle-mediated transport GO:0016192 .029 6.7
ERGIC1, ZFYVE1, and RABGEF1
Cytokine binding GO:0019955 .048 8.4
CCBP2, EBI3, and CMKLR1
Notch compared to control
Regulation of apoptosis GO:0042981 .017 3.9
DIABLO, IGFBP3, STAT1
Sterol transport GO:0015918 .021 9.3
NPC1 and CAV1
PE: pre-eclampsia, FC: fold change, GO ID: gene ontology identiﬁcation.6 Journal of Pregnancy
controls). If the distribution was signiﬁcant, a post hoc
Dunn’s multiple comparison test was used to determine
signiﬁcance between individual groups. A P-value <.05 was
considered statistically signiﬁcant.
2.5. Antibody Microarrays. An in-house designed human
recombinant antibody microarray technology platform was
appliedfortargetedproteinexpressionproﬁling[23,24].The
applicability of the technology platform has been extensively
validated [23–26] and demonstrated in various clinical
applications targeting, for example, pre-eclampsia [27]a n d
pancreatic cancer [28].
2.5.1. Extraction and Labeling of Placenta Tissue Proteins.
Predominantly water-soluble proteins were extracted from
tissue biopsies as recently described [27]. Brieﬂy, 50mg
tissuewasresuspendedin375μlextractionbuﬀer—2%(w/v)
saponin (Sigma-Aldrich, St Louis, MO, USA), 100μg/ml
soybean trypsin inhibitor (Sigma-Aldrich), 350μg/ml phe-
nylmethylsulfonyl-ﬂuoride (Sigma-Aldrich),and0.1%(w/v)
bovine serum albumin in PBS—and incubated at 4◦C
over night. After centrifugation at 13000g for 5min, the
supernatantscontainingtheextractedproteinswerecollected
a n dd i a l y z e da g a i n s tP B Sf o r7 2ha t4 ◦C. The protein con-
centration was determined using Micro BCA Protein Assay
kit (Thermo Fisher Scientiﬁc Pierce, Rockford, IL, USA)
according to the instructions provided by the manufacturer.
The samples were biotinylated, using previously opti-
mized labeling conditions [23, 24, 29]. Brieﬂy, the samples
were diluted with PBS to a ﬁnal protein concentration
of about 2mg/ml before EZ-Link Sulfo-NHS-LC-Biotin
(Thermo Fisher Scientiﬁc Pierce) was added to a ﬁnal
concentration of 0.6mM. The reaction mixture was then
incubated for 2h on ice, with vortexing every 20min.
Unreacted biotin was removed by dialysis against PBS for
72h at 4◦C. Finally, the samples were aliquoted and stored
at −20◦Cp r i o rt ou s e .
2.5.2. Production and Puriﬁcation of scFvs. Eleven human
recombinant scFv antibodies against 4 soluble proteins,
including, TGF-β1 (clones 1 to 3), VEGF (clones 1 to 4),
C5 (clones 1 and 2), and RANTES (clones 1 and 2), were
included in the study. Further, 22 additional antibodies
directed against a range of analytes were included for array-
to-array normalization (see below). The antibodies were
selected from the n-CoDeR library [30] and kindly provided
by BioInvent International AB (Lund, Sweden). Thus, some
of the antigens were recognized by up to four diﬀerent scFv
clones, which was part of the quality control of the arrays.
All scFvs were produced in E. coli. Brieﬂy, soluble scFvs,
allcarrying aC-terminal his6-tag,were puriﬁedfromexpres-
sion supernatants or periplasmic space by aﬃnity chroma-
tography on Ni2+-NTA (Qiagen, Hilden, Germany). Bound
molecules were eluted with 250mM imidazole, dialyzed
against PBS,andstoredat4◦Cuntilfurther use.Theintegrity
and degree of purity of the produced scFvs were evaluated
by 10% SDS-PAGE (Invitrogen, Carlsbad, CA, USA). The
protein concentrations were determined by measuring the
absorbance at 280nm.
2.5.3.FabricationandProcessing ofscFvAntibodyMicroarrays.
The fabrication and processing of scFv microarrays were
performed according to previously optimized techniques
[27]. Brieﬂy, scFv antibody microarrays were fabricated by
dispensing Ni2+-NTA puriﬁed scFvs (200–500μg/ml) onto
black polymer MaxiSorp slides (NUNC A/S) using the
noncontact sciFLEXARRAYER S11 (Scienion AG, Berlin,
Germany). The scFvs were arrayed, in eight replicates each,
by spotting 2 drops (300pL/drop) on top of each other (the
spots were allowed to dry out in between), and individual
subarrays were created using a hydrophobic marker pen
(DakoCytomation).
A3 6× 8 array, composed of 33 antibodies, 1 negative
control (PBS), and 2 position markers (10μg/ml Alexa-
647 labeled streptavidin in PBS) was printed per slide. The
arrays were blocked with 5% (w/v) fat-free milk powder
a n d0 . 0 5 %( v / v )T w e e n - 2 0i nP B Sf o r1ho ns h a k i n gt a b l e
and then washed two times with 0.05% (v/v) Tween-20
in PBS (PBS-T). All incubation steps were performed in
humidity chamber unless otherwise stated. Labeled tissue
extracts diluted 10 times in 1% (w/v) fat-free milk pow-
der and 1% Tween-20 in PBS (PBS-MT) were added to
arrays (100μl/slide) and incubated on a shakingtable for
1h. Subsequently, the arrays were washed two times with
PBS-T. Bound proteins were detected using 1μg/ml Alexa-
647 labeled streptavidin in PBS-MT, and incubated on
a shakingtable for 1h. The slides were washed two times
with PBS-T. Finally, the arrays were dried under a stream
of nitrogen and immediately scanned at 5μm resolution
using a confocal ﬂuorescence scanner (ScanArray Express
microarray scanner; Perkin Elmer Life Analytical Sciences).
The intensity of each spot was quantiﬁed by the ﬁxed
circle method using the ScanArray Express software V4.0
(Perkin Elmer Life Analytical Sciences). Each data point
represents the mean value of four replicates (the two highest
and two lowest replicates were automatically excluded) after
subtractinglocalbackground.Forproteinanalytesdisplaying
saturated signals, values from lower scanning settings were
scaled and used instead.
2.5.4. Data Normalization. The chip-to-chip normalization
was performed using a semiglobal normalization approach,
as previously described [30, 31]. To this end, 22 antibodies
were used to calculate a chip-to-chip normalization factor.
The normalization factor Ni was calculated by the formula
Ni=Si/u, where Si is the sum of the signal intensities of the
22 analytes for each sample, and u is the average Si from
all samples. Each dataset generated from one sample was
divided by normalization factor Ni.
2.5.5. Data Analysis. Signiﬁcantly upregulated or downregu-
lated analytes (P<. 05) were identiﬁed using Wilcoxon test
using R [32].
3.Results
We compared the gene proﬁles of PE placentas to those of
normal placentas using oligonucleotide microarrays. A total
of 35 samples were included in the experiments, 10 PEJournal of Pregnancy 7
placenta samples, 15 control placenta samples, 5 placenta
samples from patients with bilateral notching with PE, and
5 placenta samples from patients with bilateral notching
without PE (Table 1). In order to identify genes diﬀerentially
expressed between the examined groups, we performed
a false discovery rate modiﬁed t-test. To limit the number
of signiﬁcant genes a cutoﬀ of value was set, P ≤ 10
−3.
At this P-value, 148 genes were signiﬁcantly altered in at
least one group comparison. The diﬀerentially expressed
genes are listed in the supplementary table (see supplemen-
tary Material available onlinr at doi: 10.155/2011/472354).
Among the most signiﬁcantly altered genes were neural
cell adhesion molecule 1 (NCAM1), haptoglobin (HP),
transforming growth factor beta 1 (TGFB1), and inhibin
alpha (INHA)( Table 2).
In order to assess the possibility that the results obtained
derived from maternal blood in the placentas, 10 maternal
blood samples (5 PE and 5 controls) were analyzed.
Using the same P-value as above, resulted in 10 genes
with signiﬁcantly altered expression between PE and con-
trols; actin-related protein 2 (ACTR2), calponin 2 (CALP2),
and superoxide dismutase 2 (SOD2). None of theses genes
matched the altered placenta genes indicating that maternal
blood trapped in the placenta did not aﬀect the results
observed there.
Quantitative real-time PCR was used to verify the gene
microarray results. Real-time mRNA data are presented as
box-plots in Figure 1.
PE Compared to Controls. TGFB1 was higher in the PE with
and without bilateral notching than in the controls (P = .02
and P = .01, resp.). INHA showed increased expression in
the PE groups (with and without notching) versus controls
(P = .005 and .01, resp.).
PE Compared to Notch without PE. the transcription factor
Tat-interacting protein, 30kD, (TIP30) was underexpressed
in both the notch groups compared to the PE group (P =
.02) and controls (P = .04). Neural cell adhesion molecule 1
(NCAM1) was not signiﬁcantly altered in the real-timePCR
analysis. A larger sample size will be needed to validate or
invalidate the NCAM result deﬁnitively.
Notch Compared to Controls. haptoglobin (HP), a plasma
heme scavenger responsible for transporting heme to the
liver, showed lower expression in the notch group compared
to controls (P = .04).
To couple changes in gene expression to biological pro-
cesses, we performed three diﬀerent bioinformatic analyses:
gene ontology (GO), KEGG signaling pathway analysis, and
InterPro protein domain analysis (IRP). Results from the
GO and KEGG/IRP analyses are listed in Tables 3 and 4,
respectively.
When comparing genes diﬀerentially expressed in the PE
group against controls, 18 GO categories were signiﬁcantly
altered P<. 05; the most signiﬁcant changes were in genes
associated with transcription factor binding (GO:0008134,
P = .0019), negative regulation of signal transduction
(GO:0009968, P = .0027), and transcription corepressor
activity (GO:0003714, P = .0086). When performing
a signal pathway analysis, of the same genes, the neurode-
generativedisorderspathway(KEGGpathwayIDHSA01510,
P = .04) was the only one signiﬁcantly altered. This pathway
includes genes such as heat shock protein 5 and superoxide
dismutase 2. In the InterPro analysis, the category Ras small
GTPase, Rab (IPR003579) type was the only category altered
(P = .05).
W h e nc o m p a r i n gP Et ot h en o t c hg r o u p ,3 6G Oc a t e -
gories were found to be altered, although several of these
were “hierarchical duplicates,” meaning they were subgroups
within the same categorical branch. Again, the top categories
were transcription related, transcriptional activator activity
(GO:0016563, P = .0005), and transcription coactivator
activity (GO:0003713,P = .0009).Muscle ﬁber development
was also signiﬁcantly altered (GO:0048747, P = .0058). The
signaling pathway antigen processing and presenting (KEGG
pathway ID HSA04612, P = .045) showed a signiﬁcant
alteration. In the InterPro analysis, six protein domain
functions were altered. Among them, were the HEAT repeat
element (IPR000357, P = .0028) and H+ transporting
ATPase, proton pump (IPR000695, P = .0078).
In the comparison between PE with notching and
notch without PE, 19 GO categories were altered. Among
the most signiﬁcantly altered categories were chemotaxis
(GO:0006935, P = .021), positive regulation of cell
proliferation (GO:0008284, P = .026), and cytokine binding
(GO:0042102,P = .048).The ubiquitinmediated proteolysis
signaling pathway (KEGG pathway ID HSA04120, P = .02)
was altered. The InterPro analysis showed changes in ATPase
protein domains (IPR002379, P = .02).
To validate a selected diﬀerentially expressed gene, TGF-
b1, on the protein level, a recombinant antibody microarray
technology platform, optimized for sensitive serum protein
expression proﬁling, was applied. For this purpose, we
selected6PEand5controlsamplestoassay. Three additional
proteins commonly involved in inﬂammatory responses—
C5, VEGF, and RANTES—were also analyzed. It is worth
noting that the mRNA encoding the VEGF receptor, FLT1,
was found to be increased in PE samples in our DNA array
study.
TGF-β1, VEGF, C5, and RANTES were signiﬁcantly
upregulated in PE compared to controls, (P< . 05)
(Figure 2). Taken together, the data show that TGF-β1w a s
diﬀerentially expressed on both gene and protein level. Like
its receptor, VEGF protein was upregulated leveling PE
samples (FLT1, Table 2).
4.Discussion
To ﬁnd genes or mechanisms that might promote or mitigate
the development of PE, we used gene proﬁling to study
women with bilateral notching who developed or failed to
develop PE. Some of the altered genes (INHA, FLT1, HO-1,
andNCAM-1)havebeenreportedinotherstudies[8,33,34].
The V-rel reticuloendotheliosis viral oncogene homolog A
(RELA) has previously been implicated in PE and, we now
show that RELB is increased in PE as well [15]. A few HLA8 Journal of Pregnancy
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Figure 1: Microarray validation with real-time PCR. The most signiﬁcantly altered genes in the microarray analysis as well as genes of
interest were validated usingquantitative real-time PCR. Results are presented as box-plots,showinggroups’medians aswell as the 25thand
the75th percentile. β-actin wasused ashousekeeping gene, andall valuesare quotas between the gene of interest andβ-actin. Kruskal-Wallis
with post hoc Dunn was used to determine statistical signiﬁcance. ∗P<. 05, ∗∗P< . 01, ∗∗∗P<. 005 The order is as follows: (a) inhibin
α, (b) transforming growth factor β, (c) Tat-interacting protein (30kD), and (d) haptoglobin.
isoforms, HLA-G3, and HLA-DRA have previously been
shown to be either increased or decreased in PE [34, 35].
Notching in early pregnancy is considered a risk factor
for PE [9, 14]. We have previously suggested notch to be an
early form of PE [15]. Thus, one would expect the notch
group to have a diﬀerent placental gene proﬁle compared
to the control and PE groups. Indeed, our bioinformatic
analyses, as well as our previous study, show alterations in
several functional categories for the notch group. Based on
the gene expression results, we suggest that there may be
a placental mechanism that determines how PE progresses
(Figure 3). Depending on which inﬂammatory genes are
beingexpressed,theplacentamayeitherprogressfromastate
of notch to early onset PE or remain clinically asymptomatic
only showing signs of bilateral notch. One mechanism that
providesprotectionmaybetheincreasedcapacityforantigen
presentation. Overexpression of HLA genes such as HLA-B,
CD74, PSME1, and PSME2, may inhibit the inﬂammatory
processes and thereby prevent progression of PE. Recently,
we have shown that HLA-DPA1 is increased in the notch
placenta [16].
Increased gene expression and accumulation of free fetal
hemoglobin have also been shown in the PE placentas
[16]. Hemoglobin, in its free form, disrupts cell membranes
causing cytolysis and formation of reactive oxidative species
(ROS) [36, 37]. Moreover, the hemoglobin metabolites,
heme and iron, are both potent redox agents disrupting cell
membranes and membrane proteins by cytolysis. Due to itsJournal of Pregnancy 9
Table 4: Results from the KEGG signaling pathway analyses and the InterPro protein domainanalyses.
KEGG pathway analyses KEGG ID P-value FC
Pathway
PE compared to controls
Neurodegenerative disorders HSA01510 .04 9.1
SOD1 and PSEN1
PE without notch compared to notch
Antigen processing and presentation HSA04612 .04 3.1
HLA-B, HSP90AA1, PSME2, and CD74
PE with notch compared to notch
Ubiquitin mediated proteolysis HSA04120 .02 12.0
UBE2E2, TCEB2, and ANAPC2
Notch compared to controls
Leukocyte transendothelial migration HSA04670 .03 5.7
ACTG1, FKSG30, CXCR4, and CLDN5
Focal adhesion HSA04510 .03 4.0
ACTG1, FKSG30, FLT1, and CAV1
InterPro protein domainanalyses InterPro ID P-value FC
InterPro term
PE compared to controls
HEAT IPR000357 .05 4.5
TNPO1 and PPP2R1A
Ras small GTPase, Rab type IPR003579 .05 3.6
RAB9B, RAB17, and RHOH
PE compared to notch
HEAT IPR000357 .003 4.3
ARMC8, IPO13, PPP1R12B, and GCN1L1
H+ transporting ATPase, proton pump IPR000695 .008 21.4
ATP13A1 and ATP2A2
Haloacid dehalogenase-like hydrolase IPR005834 .01 5.7
ATP13A2, ATP13A1, and ATP2A2
PE with notch compared to notch
ATPase, F0/V0 complex IPR002379 .02 7.4
ATP6V0C and ATP5G1
Notch compared to controls
Actin IPR004001 .04 44.1
ACTG1 and FKSG30
P E :p r e - e c l a m p s i a ,F C :f o l dc h a n g e .
lipophilicnature, heme crosses cell membranes and damages
cytosolic proteins, organelles, and DNA [38]. Furthermore,
heme is a proinﬂammatory substance that stimulates both
neutrophil activation and migration [39, 40]. There is
an increased number of fetal cells, cell debris, and free
fetal hemoglobin crossing over the damaged blood-placenta
barrier into the maternal system [41, 42]. The notch placenta
shows similar vascular damage as in PE. Fetal cells and cell
debris may, therefore, also leak into the maternal circula-
tion in the notch placenta. Increased expression of HLA-
genes and other genes responsible for antigen processing
may result in an increased immune defense in the notch
placenta. Hence, notch placentas may not develop the same
inﬂammatory response as seen in notch with PE and PE.
In fact, genes related to inﬂammation were unaltered in the
notch placenta.
When comparing PE with and without notch to
notch without PE, we found pro-inﬂammatory genes with
increasedexpression,TGFB1,INHA,andchemokineligand8
(CCL8). Among the most signiﬁcantly altered GO functional
categories are chemotaxis and locomotory behavior. Thus,
PE with notching appears to be associated with increased
cellular movement compared to notching only. More specif-
ically, the mode of cellular movement appears to be induced
by genes related to chemotaxis that were overexpressed. The
GO functional category cytokine binding (GO:0019955) was
also upregulated, suggesting that a cytokine gradient may
be responsible for the chemotaxis in PE with notching.10 Journal of Pregnancy
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Figure 2: Protein expression validation with antibody microarray.
Protein expression proﬁling of PE (grey bars) versus N (open
bars) using recombinant antibody microarray analysis. A focused
microarray composed of 11 scFv antibodies directed against 4
proteins, including TGF-β1, VEGF, C5, and RANTES was applied.
Six PE samples and ﬁve control samples were analysed. The index
(1), and so forth, indicate the clone number of the antibody used,
meaningthat severalclonestargeting diﬀerent epitopes on the same
analyte was used to further strengthen the data. The expression
levels between PE and N were found to be signiﬁcant (P<. 05) for
all four analytes.
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Figure3:Pathophysiology.Basedonthegeneexpressionresults,we
suggest that there may be a placental mechanism that determines
how PE progresses from stage one, characterized by inadequate
perfusion of the placenta, to the clinical symptoms in stage two.
Depending on which inﬂammatory genes that are expressed, the
placenta may either progress from a state of notch to early onset PE
or remain clinically asymptomatic only showing signs of bilateral
notch.
Immunologically derived cells proliferate in response to
cytokine gradients. In fact, T-cell proliferation was yet
another category altered in the comparison between PE
with notch and notch without PE. The progression from
notch to PE may, therefore, be driven by induction of
inﬂammation within the placenta. PE is known to be
associated with increased levels of several pro-inﬂammatory
cytokines, including interleukins −6, −8, and the tumor
necrosis factor α (TNFα)[ 43, 44]. Moreover, genes related
to the central inﬂammatory NF-kappa B pathway are altered
in the PE placentas, which may explain the increase of pro-
inﬂammatory factors in PE [15, 45]. Our results suggest that
the notch state may be more than a risk factor, it may be
a stepping stone towards PE, bridging an early decrease in
placental perfusion with the ﬁnal inﬂammatory steps needed
toprogressinto thesecondstageofPE.Byusing theantibody
array methodology, we have been able to display diﬀerent
inﬂammatory signatures between early and late-onset PE,
further underlining the importance of inﬂammation in the
PE pathogenesis [46].
Several confounding factors may contribute to the gene
expression revealed by microarrays. Gestational age and
mode of delivery are such factors. A placenta delivered at
35gw diﬀers from a term placenta. Due to the fact that
there is no treatment for PE, the gestational ages of the
included PE cases were generally lower than those of the
controls. Although we aimed to match the groups based on
gestational age, one early onset PE case was included in the
PE group. Placentas from vaginal deliveries have been shown
to have increased activity in the pro-inﬂammatory pathway
NF-kappa B as well as increased levels of pro-inﬂammatory
cytokines compared to placentas from Caesarian sections
[47]. Hence, mode of delivery may well aﬀect the gene
expression and contribute to some of the changes seen in the
study.
In this discovery study, we have performed gene expres-
sion analysis on both placenta and maternal blood, and
validated targeted analytes on the protein level as well,
to further enhance our fundamental knowledge of PE.
Although these ﬁndings need to be validated and extended
analysing novel, independent cohorts containing larger
numbers of samples, the work has provided a clue about
the pathophysiology of PE. Pro-inﬂammatory genes may
drive the placenta towards PE, and protective genes may
have the opposite eﬀect. More speciﬁcally, the ﬁrst stage,
poor placentation, induces ROS formation and damage
to the blood-placenta barrier as previously suggested [6].
A possible intermediate step may be brought on by increased
apoptosis, activation of inﬂammatory pathways, imbalance
in antioxidation, and increased vascular resistance as seen
in bilateral notch. As the placenta attracts and/or activates
immune cells, inﬂammation and irreversible damage to
the blood-placenta barrier may occur. Increased, expression
of HLA and antigen-presenting genes may ameliorate the
inﬂammatory response.
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